HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plumbagin, isolated from Plumbago zeylanica, induces cell death through apoptosis in human pancreatic cancer cells.

AbstractBACKGROUND AND AIMS:
Pancreatic cancer is one of the most resistant malignancies. Several studies have indicated that plumbagin isolated from Plumbago zeylanica possesses anticancer activity. However, its antitumor effects against pancreatic cancer have not been explored.
METHODS:
We investigated the effect of plumbagin on the growth of human pancreatic carcinoma cells and its possible underlying mechanisms.
RESULTS:
Plumbagin inhibited the growth of Panc-1 and Bxpc-3 cells in a dose-dependent and time-dependent manner. Liu's staining and transmission electron microscopy demonstrated morphological changes resembling apoptosis in Panc-1 cells treated with plumbagin. The degree of apoptosis was assessed by measuring the proportions of sub-G(1), annexin V+/propidium iodide-, and terminal- deoxynucleotidyl-transferase-mediated-nick-end labeling (TUNEL)+ cells, and a significant increment in apoptotic cells was observed. Exposure to plumbagin caused the upregulation of Bax, a rapid decline in mitochondrial transmembrane potential, apoptosis-inducing factor overexpression in cytosol, and the cleavage of procaspase-9 and poly ADP-ribose polymerase. Activation of caspase-3, but not caspase-8, was evidenced by fluorometric substrate assay. Pretreatment with caspase inhibitors did not block plumbagin-induced apoptosis. Alternatively, it is possible that plumbagin downregulated phosphoinositide 3-kinase activity through a negative feedback mechanism. In an orthotopic pancreatic tumor model, plumbagin markedly inhibited the growth of Panc-1 xenografts without any significant effect on leukocyte counts or body weight.
CONCLUSION:
Plumbagin may induce apoptosis in human pancreatic cancer cells primarily through the mitochondria-related pathway followed by both caspase-dependent and caspase-independent cascades. It indicates that plumbagin can be potentially developed as a novel therapeutic agent against pancreatic cancer.
AuthorsChien-An Chen, Hen-Hong Chang, Chung-Yu Kao, Tung-Hu Tsai, Yu-Jen Chen
JournalPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (Pancreatology) Vol. 9 Issue 6 Pg. 797-809 ( 2009) ISSN: 1424-3911 [Electronic] Switzerland
PMID20110748 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 S. Karger AG, Basel.
Chemical References
  • Antineoplastic Agents
  • Naphthoquinones
  • bcl-2-Associated X Protein
  • Caspases
  • plumbagin
Topics
  • Animals
  • Antineoplastic Agents (isolation & purification, therapeutic use)
  • Apoptosis
  • Carcinoma (drug therapy)
  • Caspases (metabolism)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Humans
  • Membrane Potential, Mitochondrial (drug effects)
  • Mice
  • Mice, Nude
  • Naphthoquinones (isolation & purification, therapeutic use)
  • Pancreatic Neoplasms (drug therapy)
  • Plumbaginaceae (chemistry)
  • Xenograft Model Antitumor Assays
  • bcl-2-Associated X Protein (analysis, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: